Profound Medical Corp. (PROF): Total Liabilities
$11.04M
As of 2025-12-31
$12.58M
As of 2026-06-30
| Period ended | Total Liabilities | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $11.04M | +12.5% | 2026-03-05, Balance as of period end |
| 2024-12-31 | $9.81M | -22.9% | 2026-03-05, Balance as of period end |
| 2023-12-31 | $12.73M | n/a | 2025-03-07, Balance as of period end |
Total Liabilities at similar companies
| Company | Year ended | Total Liabilities | Change YoY |
|---|---|---|---|
| Profound Medical Corp. (PROF) | 2025-12-31 | $11.04M | +12.5% |
| Biotricity Inc. (BTCY) | 2026-03-31 | $39.41M | +10.5% |
| Allurion Technologies, Inc. (ALUR) | 2025-12-31 | $92.96M | -16.1% |
| Vivos Therapeutics, Inc. (VVOS) | 2025-12-31 | $26.70M | +264.3% |
| Nephros Inc (NEPH) | 2025-12-31 | $3.44M | +31.0% |
| Sonoma Pharmaceuticals, Inc. (SNOA) | 2026-03-31 | $10.87M | +17.1% |
| Spectral AI, Inc. (MDAI) | 2025-12-31 | $27.13M | +40.2% |
| Baird Medical Investment Holdings Ltd (BDMD) | 2025-12-31 | $38.48M | +0.7% |
| Nexgel, Inc. (NXGL) | 2025-12-31 | $5.57M | +13.6% |
Compare PROF, BTCY, ALUR, VVOS side by side · Screen every company in Surgical & Medical Instruments & Apparatus ↗